Nve Corp /New/ (NVEC) Stock Price & Analysis
Nve Corp /New/ (NVEC) fell 1.59% to USD 105.17 as of June 10, 2026 at 00:43 UTC, according to Nexqual real-time market data.
NVEC last closed at USD 106.87; the session ranged USD 97.53–109.92 on volume of 625,215 shares. Market capitalization is $508.72M, with a 52-week range of USD 57.21–114.36 (NCM). Source: Nexqual, June 10, 2026 at 00:43 UTC.
Key Statistics (as of June 10, 2026 at 00:43 UTC)
| Price | USD 105.17 |
|---|---|
| Change | ▼ 1.59% (down) |
| Previous Close | USD 106.87 |
| Open | USD 108.17 |
| Day Range | USD 97.53 – 109.92 |
| 52-Week Range | USD 57.21 – 114.36 |
| Volume | 625,215 shares |
| Market Cap | $508.72M |
| Exchange | NCM |
Technical Analysis (NVEC)
Nexqual's technical model rates NVEC "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:43 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.09 (neutral) |
| vs SMA50 | Above (USD 86.22) |
| MACD | 6.19 (positive) |
Analyst Ratings (NVEC)
Wall Street analysts rate NVEC "None", per Nexqual as of June 10, 2026 at 00:43 UTC.
| Consensus Rating | None |
|---|
Earnings (NVEC)
| Next Earnings Date | 2026-07-22 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2017-09-30 | USD 0.65 vs est 0.61 ▲ beat |
| 2017-06-30 | USD 0.68 vs est 0.66 ▲ beat |
| 2017-03-31 | USD 0.62 vs est 0.71 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Financials & Fundamentals (NVEC)
| Total Revenue | $26.33M |
|---|---|
| Revenue Growth (YoY) | +5.30% |
| Gross Margin | +78.73% |
| Operating Margin | +61.85% |
| Profit Margin | +57.72% |
| ROE | +25.22% |
| Debt / Equity | 1.56 |
| Current Ratio | 28.21 |
| Total Cash | $19.84M |
| Total Debt | $905,539 |
| Free Cash Flow | $7.32M |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Financial Health Score (NVEC)
Nexqual rates Nve Corp /New/'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:43 UTC.
| Growth | Mixed — Revenue +2.2% YoY (annual), slow |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $20M cash, no debt |
| Cash Flow | Strong — FCF $7M, 26% margin |
| Efficiency | Strong — ROE 25%, ROA 16.0% |
Ownership (NVEC)
| Insider Ownership | +1.28% |
|---|---|
| Institutional Ownership | +88.60% |
| Shares Outstanding | 4.84M |
| Float | 4.78M |
| Short % of Float | +8.58% |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
Leadership (NVEC)
Nve Corp /New/ is led by Daniel A. Baker (age 67), CEO, President & Director, per Nexqual as of June 10, 2026 at 00:43 UTC.
| CEO, President & Director | Daniel A. Baker (age 67) |
|---|---|
| Vice President of Advanced Technology | Peter G. Eames (age 49) |
| Vice President of New Business Development | John K. Myers (age 76) |
Major Backers & Investors (NVEC)
Notable institutional backers of Nve Corp /New/ include Penserra Capital Management LLC, Defiance Etfs, LLC, ETF Series Solutions-Defiance Quantum ETF, according to Nexqual as of June 10, 2026 at 00:43 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Penserra Capital Management LLC | 12% |
| Defiance Etfs, LLC | 12% |
| ETF Series Solutions-Defiance Quantum ETF | 12% |
| Royce & Associates LP | 4.74% |
| ROYCE FUND-Royce Small-Cap Special Equity Fund | 4.7% |
| Renaissance Technologies | 3.59% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.46% |
| BlackRock | 10.05% |
| State Street | 5.4% |
| Geode Capital | 3% |
Source: Nexqual, June 10, 2026 at 00:43 UTC.
From Nve Corp /New/'s Latest SEC 10-K Filing (filed 2026-05-06)
Key Strengths & Strategy (as disclosed to the SEC)
- We protect our proprietary technology and intellectual property by seeking patents, trademarks, and copyrights, and by maintaining trade secrets by entering into confidentiality agreements with employees, suppliers, customers, and prospective customers depending on the circumstances.
- We face various cybersecurity threats, including threats to our information technology infrastructure and attempts to gain access to our proprietary or classified information, and denial-of-service and distributed denial-of-service attacks.
- Also, our confidentiality agreements may not provide meaningful protection of our proprietary information.
- Our inability to maintain our proprietary rights could have a material adverse effect on our business, financial condition, and results of operations. 11 Table of Contents Risks Related to Our Industry   We face an uncertain economic environment in the industries we serve, which could adversely affect our business.
Partnerships
- We have agreements with certain customers, including a Supplier Partnering Agreement, as amended, with Abbott Laboratories, which expires December 31, 2027.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLSN | Solesence, Inc. | USD 1.22 | ▼ 6.87% |
| VECO | Veeco Instruments Inc. | USD 67.19 | ▲ 14.95% |
| ALTI | AlTi Global, Inc. | USD 2.81 | ▼ 5.7% |
| NGEN | NervGen Pharma Corp. | USD 1.81 | ▼ 2.69% |
| ACCL | Acco Group Holdings Limited | USD 1.52 | ▼ 1.94% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:43 UTC. This page is informational and not investment advice.